Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Ethnopharmacological relevance</h3><p>Mu opioid receptor (MOR) is mainly a drug target for analgesia. Opioid-like agonists such as morphine have been clinically used for analgesia but have potential adverse effects. MOR antagonists have been demonstrated to alleviate these side effects. Plants (<em>Carthamus tinctorius</em> L, <em>Cynanchum otophyllum C. K. Schneid</em>., <em>Coffea arabica</em> L., <em>Prinsepia utilis Royle</em> and <em>Lepidium meyenii Walp.</em>) and <em>Ganoderma</em> fungi (<em>Ganoderma hainanense J. D. Zhao</em>, <em>Ganoderma capense (Lloyd) Teng</em>, <em>Ganoderma cochlear (Blume et Nees) Bres.</em>, <em>Ganoderma resinaceum Boud</em> and <em>Ganoderma applanatum (Pers.) Pat.</em>) are traditional medicines with beneficial effects on immunoregulation, analgesia and the nervous system, but whether MORs are engaged in their effects remains unknown.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aim of the study</h3><p>This work aimed to identify MOR ligands among compounds isolated from the above-mentioned 10 species, and to investigate selectivity against four opioid receptor subtypes. By analyzing the structure-activity relationship and off-target effects, we could provide a new direction for the future development of MOR drugs.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and methods</h3><p>Four opioid receptor subtype models, including MOR, delta (DOR), kappa (KOR) and nop (NOR), were established with a label-free phenotypic dynamic mass redistribution assay to systematically profile the pharmacological properties of known ligands. Then, 82 natural compounds derived from the 10 species were screened against MOR to identify new ligands. The selectivity of the new ligands was characterized against the four subtypes, and off-target effects were also investigated on eight G protein-coupled receptors (GPCRs).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The pharmacological properties of known ligands on transfected HEK293T-MOR, HEK293-DOR, HEK293-KOR and HEK293-NOR cell lines were characterized. Seven compounds purified from <em>Ganoderma cochlear (Blume et Nees) Bres.</em> and <em>Carthamus tinctorius</em> L were MOR antagonists with micromolar potency. Among them, compound <strong>35</strong> showed the strongest antagonistic activity on MOR with an IC<sub>50</sub> value of 10.0 ± 3.0 μM. To a certain extent, these seven new antagonists, exhibited antagonistic activity on the other opioid receptor subtypes, and they had almost no effect on other GPCRs, including CB1, CB2, M2 and beta2AR. Additionally, a compound from <em>Lepidium meyenii Walp.</em> displayed MOR agonistic activity.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>The established screening models opened new avenues for the discovery and evaluation of opioid receptor ligand selectivity. Together, the novel MOR antagonists and agonists will enrich the inventory of MOR ligands and benefit related therapies.</p>

Studies on action receptor to natural product epibatidine

Studies on structure-activity relationship of epibatidine and its analogues

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

Treating neuropathic pain and nicotine dependence: Epibatidine derivatives as potential therapeutics

Binding Mode Analyses of NAP Derivatives As Mu Opioid Receptor Selective Ligands Through Docking Studies and Molecular Dynamics Simulation

Research Development of Epibatidine, A New Type of Non-addicted Analgesic Compound

Design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective Antagonists

Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Structure activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the 'message-address concept' to comprehend their functional conversion.

Pharmacological profiles and anti-inflammatory activity of pCN-diEPP and mCN-diEPP, new alpha9alpha10 nicotinic receptor ligands

Molecular Modeling on Kappa Opioid Receptor and Its Interaction with Nonpeptide Kappa Opioid Agonists

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

Exploring the Putative Mechanism of Allosteric Modulations by Mixed-Action Kappa/mu Opioid Receptor Bitopic Modulators.

Nociceptive and antinociceptive responses to intrathecally administered nicotinic agonists

Computational Methods for Understanding the Selectivity and Signal Transduction Mechanism of Aminomethyl Tetrahydronaphthalene to Opioid Receptors

To probe interaction of morphine and IBNtxA with 7TM and 6TM variants of the human μ-opioid receptor using all-atom molecular dynamics simulations with an explicit membrane

Synthesis and Biological Evaluation of Novel Biased Mu-Opioid Receptor Agonists

Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products